Nektar TherapeuticsNASDAQ:NKTR
- LAST PRICE1.1400
- TODAY'S CHANGE (%)0.0100 (0.8850%)
- Bid / Lots1.0900/ 65
- Ask / Lots1.1700/ 3
- Open / Previous Close1.1300 / 1.1300
- Day Range
- 52 Week Range
- Volume962,009
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NKTR |
|---|---|---|
| 09:32 ET | 5822 | 1.1497 |
| 09:33 ET | 4877 | 1.145 |
| 09:35 ET | 1048 | 1.145 |
| 09:39 ET | 100 | 1.145 |
| 09:42 ET | 6476 | 1.135 |
| 09:44 ET | 100 | 1.14 |
| 09:46 ET | 200 | 1.135 |
| 09:48 ET | 10500 | 1.135 |
| 09:50 ET | 5750 | 1.145 |
| 09:51 ET | 700 | 1.14 |
| 09:53 ET | 21333 | 1.14 |
| 09:55 ET | 3500 | 1.14 |
| 09:57 ET | 2400 | 1.14 |
| 10:02 ET | 9753 | 1.135 |
| 10:04 ET | 645 | 1.13 |
| 10:06 ET | 1000 | 1.13 |
| 10:08 ET | 400 | 1.13 |
| 10:09 ET | 210 | 1.13 |
| 10:11 ET | 300 | 1.13 |
| 10:13 ET | 8030 | 1.135 |
| 10:18 ET | 4135 | 1.135 |
| 10:20 ET | 10871 | 1.12 |
| 10:22 ET | 10121 | 1.125 |
| 10:24 ET | 39264 | 1.135 |
| 10:26 ET | 687 | 1.13 |
| 10:27 ET | 18628 | 1.125 |
| 10:29 ET | 2061 | 1.13 |
| 10:31 ET | 1500 | 1.125 |
| 10:33 ET | 2500 | 1.125 |
| 10:36 ET | 80599 | 1.125 |
| 10:38 ET | 800 | 1.13 |
| 10:40 ET | 1536 | 1.13 |
| 10:42 ET | 3168 | 1.13 |
| 10:44 ET | 1200 | 1.13 |
| 10:45 ET | 1200 | 1.13 |
| 10:47 ET | 1915 | 1.13 |
| 10:49 ET | 11050 | 1.13 |
| 10:51 ET | 2300 | 1.13 |
| 10:54 ET | 865 | 1.13 |
| 10:56 ET | 500 | 1.13 |
| 10:58 ET | 1469 | 1.125 |
| 11:00 ET | 3023 | 1.125 |
| 11:02 ET | 1800 | 1.125 |
| 11:03 ET | 300 | 1.125 |
| 11:05 ET | 400 | 1.125 |
| 11:07 ET | 388 | 1.125 |
| 11:09 ET | 800 | 1.125 |
| 11:12 ET | 500 | 1.125 |
| 11:14 ET | 818 | 1.12 |
| 11:16 ET | 400 | 1.12 |
| 11:18 ET | 1059 | 1.12 |
| 11:20 ET | 39128 | 1.1118 |
| 11:21 ET | 200 | 1.11 |
| 11:23 ET | 1100 | 1.115 |
| 11:25 ET | 3459 | 1.115 |
| 11:27 ET | 4700 | 1.12 |
| 11:30 ET | 300 | 1.12 |
| 11:32 ET | 8509 | 1.115 |
| 11:34 ET | 5400 | 1.115 |
| 11:36 ET | 400 | 1.115 |
| 11:38 ET | 3800 | 1.11 |
| 11:39 ET | 6590 | 1.11 |
| 11:41 ET | 7646 | 1.1174 |
| 11:43 ET | 700 | 1.11 |
| 11:45 ET | 200 | 1.115 |
| 11:48 ET | 600 | 1.11 |
| 11:50 ET | 300 | 1.115 |
| 11:52 ET | 400 | 1.115 |
| 11:54 ET | 814 | 1.115 |
| 11:56 ET | 2095 | 1.115 |
| 11:57 ET | 300 | 1.115 |
| 11:59 ET | 400 | 1.11 |
| 12:01 ET | 1290 | 1.115 |
| 12:03 ET | 404 | 1.11 |
| 12:06 ET | 15219 | 1.105 |
| 12:08 ET | 500 | 1.105 |
| 12:10 ET | 262696 | 1.125 |
| 12:12 ET | 2750 | 1.125 |
| 12:14 ET | 714 | 1.12 |
| 12:15 ET | 1512 | 1.125 |
| 12:17 ET | 7291 | 1.13 |
| 12:19 ET | 1500 | 1.125 |
| 12:21 ET | 5109 | 1.125 |
| 12:24 ET | 2600 | 1.12 |
| 12:26 ET | 1300 | 1.125 |
| 12:28 ET | 1000 | 1.125 |
| 12:30 ET | 900 | 1.125 |
| 12:32 ET | 4425 | 1.125 |
| 12:33 ET | 600 | 1.125 |
| 12:35 ET | 700 | 1.125 |
| 12:37 ET | 800 | 1.125 |
| 12:39 ET | 700 | 1.125 |
| 12:42 ET | 41854 | 1.135 |
| 12:44 ET | 1500 | 1.135 |
| 12:46 ET | 19687 | 1.145 |
| 12:48 ET | 5287 | 1.14 |
| 12:50 ET | 2520 | 1.14 |
| 12:51 ET | 4771 | 1.145 |
| 12:53 ET | 1343 | 1.145 |
| 12:55 ET | 1000 | 1.14 |
| 12:57 ET | 4573 | 1.145 |
| 01:00 ET | 124788 | 1.14 |
Nov 18, 2024
Nov 7, 2024
Nektar Therapeutics Reports Third Quarter 2024 Financial Results, from 4:15PM ET on Thursday Nov 07, 2024 by Dow Jones
4:15PM ET on Thursday Nov 07, 2024 by Dow Jones*DJ Nektar Therapeutics 3Q Loss/Shr 18c >NKTR, from 4:15PM ET on Thursday Nov 07, 2024 by Dow Jones
4:15PM ET on Thursday Nov 07, 2024 by Dow JonesNektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting, from 10:15AM ET on Thursday Nov 07, 2024 by Dow Jones
10:15AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Nektar Therapeutics to Participate in Upcoming Investor Conferences, from 6:00PM ET on Wednesday Nov 06, 2024 by Dow Jones
6:00PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nektar Therapeutics | 208.4M | -1.4x | --- |
2Seventy Bio Inc | 190.4M | -2.2x | --- |
Alector Inc | 251.7M | -1.5x | --- |
Editas Medicine Inc | 182.4M | -0.9x | --- |
ADC Therapeutics SA | 218.5M | -1.0x | --- |
SAGE Therapeutics Inc | 339.5M | -1.0x | --- |
Company Information
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
Contact Information
- Headquarters
- 455 Mission Bay Boulevard SouthSAN FRANCISCO, CA, United States 94158
- Phone
- 415-482-5300
- Fax
- 415-339-5300
Executives
- Independent Chairman of the Board
- Robert Chess
- President, Chief Executive Officer
- Howard Robin
- Interim Chief Financial Officer
- Sandra Gardiner
- Senior Vice President, Chief Legal Officer
- Mark Wilson
- Chief Research and Development Officer
- Jonathan Zalevsky
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $208.4M |
|---|---|
Revenue (TTM) | $93.1M |
Shares Outstanding | 184.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $-0.84 |
Book Value | $0.68 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -164.34% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
